Theratechnologies 

$3.39
25
+$0+0% Thursday 19:59

Statistics

Day High
3.4
Day Low
3.34
52W High
3.4
52W Low
1.12
Volume
3,272,893
Avg. Volume
432,777
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

9OctExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
-0.24
-0.14
-0.04
0.06
Expected EPS
0.0356
Actual EPS
N/A

Financials

-9.67%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
85.87MRevenue
-8.31MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow THTX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen develops therapies in areas similar to Theratechnologies, focusing on serious illnesses including oncology, which competes with Theratechnologies' work in HIV-related cancers.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a direct competitor in the HIV and infectious disease space, offering treatments that could be alternatives to Theratechnologies' products.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals competes in creating innovative therapies for serious diseases, potentially overlapping with Theratechnologies' market in metabolic disorders and conditions related to HIV.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on developing drugs for neurological and neurodegenerative diseases, competing indirectly with Theratechnologies by targeting similar patient demographics with complex conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals competes in the biopharmaceutical field, focusing on innovative treatments that could rival Theratechnologies' products in metabolic diseases and conditions associated with HIV.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV focuses on developing novel modes of action, which could compete with Theratechnologies in the area of innovative treatments for various diseases, including those related to metabolic and infectious diseases.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in similar therapeutic areas as Theratechnologies, including HIV, and its broad portfolio in immunology and oncology could present competitive pressures.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse range of products that compete across several of Theratechnologies' interest areas, including treatments for infectious diseases and cancer.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company that offers products directly competing with Theratechnologies, especially in the fields of infectious diseases and cancer.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk is a leading company in diabetes and metabolic disorder treatments, areas where Theratechnologies is also aiming to make an impact.

About

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Show more...
CEO
Mr. Paul Lévesque
Employees
103
Country
CA
ISIN
CA88338H1001

Listings

0 Comments

Share your thoughts

FAQ

What is Theratechnologies stock price today?
The current price of THTX is $3.39 USD — it has increased by +0% in the past 24 hours. Watch Theratechnologies stock price performance more closely on the chart.
What is Theratechnologies stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Theratechnologies stocks are traded under the ticker THTX.
Is Theratechnologies stock price growing?
THTX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Theratechnologies has showed a +140.43% increase.
What is Theratechnologies revenue for the last year?
Theratechnologies revenue for the last year amounts to 85.87M USD.
What is Theratechnologies net income for the last year?
THTX net income for the last year is -8.31M USD.
How many employees does Theratechnologies have?
As of April 03, 2026, the company has 103 employees.
In which sector is Theratechnologies located?
Theratechnologies operates in the Health Care sector.
When did Theratechnologies complete a stock split?
The last stock split for Theratechnologies was on July 31, 2023 with a ratio of 1:4.
Where is Theratechnologies headquartered?
Theratechnologies is headquartered in Montreal, CA.